Carcinoma Cervix
• MBBS Exam – 10 Slide Presentation
• Name: Likhith R Shekar
Introduction & Epidemiology
• • Malignancy of uterine cervix
• • Most common gynecological cancer in India
• • Peak age: 40–60 years
Etiology & Risk Factors
• • Persistent HPV infection (16, 18)
• • Early sexual activity
• • Multiple partners
• • Multiparity, smoking
• • Immunosuppression
Pathology
• • Squamous cell carcinoma – most common
• • Adenocarcinoma
• • Preinvasive phase: CIN I–III
Natural History
• • Normal epithelium → CIN → Invasive cancer
• • Long latent period
• • Allows effective screening
Clinical Features
• • Early: asymptomatic
• • Post-coital bleeding
• • Intermenstrual bleeding
• • Foul vaginal discharge
• • Pelvic pain (late)
Spread
• • Local: vagina, parametrium
• • Lymphatic: pelvic → para-aortic nodes
• • Hematogenous: lung, liver, bone
FIGO Staging (Table)
• • Stage I: Confined to cervix
• • Stage IA: Microinvasion
• • Stage IB: Clinically visible lesion
• • Stage II: Beyond cervix, not pelvic wall
• • Stage III: Pelvic wall / lower 1/3 vagina
• • Stage IV: Bladder, rectum or distant mets
Diagnosis
• • Pap smear – screening test
• • HPV DNA testing
• • Colposcopy with biopsy
• • Imaging (MRI/CT) for staging
Treatment & Prevention
• • Early stage: Surgery (Wertheim’s)
• • Locally advanced: Chemoradiation
• • Prevention: HPV vaccine, Pap smear

Ca_Cervix_10_Slides_with_FIGO_MBBS.pptx.

  • 1.
    Carcinoma Cervix • MBBSExam – 10 Slide Presentation • Name: Likhith R Shekar
  • 2.
    Introduction & Epidemiology •• Malignancy of uterine cervix • • Most common gynecological cancer in India • • Peak age: 40–60 years
  • 3.
    Etiology & RiskFactors • • Persistent HPV infection (16, 18) • • Early sexual activity • • Multiple partners • • Multiparity, smoking • • Immunosuppression
  • 4.
    Pathology • • Squamouscell carcinoma – most common • • Adenocarcinoma • • Preinvasive phase: CIN I–III
  • 5.
    Natural History • •Normal epithelium → CIN → Invasive cancer • • Long latent period • • Allows effective screening
  • 6.
    Clinical Features • •Early: asymptomatic • • Post-coital bleeding • • Intermenstrual bleeding • • Foul vaginal discharge • • Pelvic pain (late)
  • 7.
    Spread • • Local:vagina, parametrium • • Lymphatic: pelvic → para-aortic nodes • • Hematogenous: lung, liver, bone
  • 8.
    FIGO Staging (Table) •• Stage I: Confined to cervix • • Stage IA: Microinvasion • • Stage IB: Clinically visible lesion • • Stage II: Beyond cervix, not pelvic wall • • Stage III: Pelvic wall / lower 1/3 vagina • • Stage IV: Bladder, rectum or distant mets
  • 9.
    Diagnosis • • Papsmear – screening test • • HPV DNA testing • • Colposcopy with biopsy • • Imaging (MRI/CT) for staging
  • 10.
    Treatment & Prevention •• Early stage: Surgery (Wertheim’s) • • Locally advanced: Chemoradiation • • Prevention: HPV vaccine, Pap smear